Evaluation of safety
ADVERSE EVENT
Participants were allowed to immediately inform the investigator and discontinue the capsules if they had any difficulty or challenge during the study. Adverse events were monitored by physician interviews and blood tests and surveyed using questionnaires after the 12-week intervention.